MUC5B and neoplasm: Another pathological analysis of NSCLC patients carrying EGFR mutations revealed that MUC5B expression levels in tumor tissues were strongly associated with patient overall survival, indicating that MUC5B may act as a novel prognostic biomarker in this subgroup [25].